DK0966685T3 - Protein-fragment-komplementationsassays til påvisning af biomolekylære interaktioner - Google Patents

Protein-fragment-komplementationsassays til påvisning af biomolekylære interaktioner

Info

Publication number
DK0966685T3
DK0966685T3 DK98901905T DK98901905T DK0966685T3 DK 0966685 T3 DK0966685 T3 DK 0966685T3 DK 98901905 T DK98901905 T DK 98901905T DK 98901905 T DK98901905 T DK 98901905T DK 0966685 T3 DK0966685 T3 DK 0966685T3
Authority
DK
Denmark
Prior art keywords
dhfr
fragments
leucine
zipper
fragment
Prior art date
Application number
DK98901905T
Other languages
Danish (da)
English (en)
Inventor
Stephen William Watso Michnick
Joelle Nina Apartmen Pelletier
Ingrid Remy
Original Assignee
Odyssey Thera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odyssey Thera Inc filed Critical Odyssey Thera Inc
Application granted granted Critical
Publication of DK0966685T3 publication Critical patent/DK0966685T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK98901905T 1997-01-31 1998-02-02 Protein-fragment-komplementationsassays til påvisning af biomolekylære interaktioner DK0966685T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002196496A CA2196496A1 (en) 1997-01-31 1997-01-31 Protein fragment complementation assay for the detection of protein-protein interactions
PCT/CA1998/000068 WO1998034120A1 (en) 1997-01-31 1998-02-02 Protein fragment complementation assays to detect biomolecular interactions

Publications (1)

Publication Number Publication Date
DK0966685T3 true DK0966685T3 (da) 2005-12-19

Family

ID=4159802

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98901905T DK0966685T3 (da) 1997-01-31 1998-02-02 Protein-fragment-komplementationsassays til påvisning af biomolekylære interaktioner

Country Status (10)

Country Link
US (7) US6270964B1 (de)
EP (2) EP0966685B9 (de)
JP (1) JP4262778B2 (de)
AT (1) ATE301835T1 (de)
AU (1) AU5850598A (de)
CA (1) CA2196496A1 (de)
DE (1) DE69831136T2 (de)
DK (1) DK0966685T3 (de)
ES (1) ES2247673T3 (de)
WO (1) WO1998034120A1 (de)

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306914B2 (en) * 1997-01-31 2007-12-11 Odyssey Thera Inc. Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy
US6897017B1 (en) * 1997-01-31 2005-05-24 Odyssey Thera Inc. Vivo library-versus-library selection of optimized protein-protein interactions
US7062219B2 (en) * 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
CA2196496A1 (en) * 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US20020064769A1 (en) * 2000-10-05 2002-05-30 Watson Michnick Stephen William Dynamic visualization of expressed gene networks in living cells
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
AU736836B2 (en) 1997-07-07 2001-08-02 Medical Research Council In vitro sorting method
US6333154B1 (en) * 1997-12-04 2001-12-25 Institut Pasteur Bacterial multi-hybrid system and applications thereof
US20050221280A1 (en) * 1998-02-02 2005-10-06 Odyssey Thera, Inc. Protein-protein interactions for pharmacological profiling
US7166424B2 (en) * 1998-02-02 2007-01-23 Odyssey Thera Inc. Fragments of fluorescent proteins for protein fragment complementation assays
US6828099B2 (en) * 1998-02-02 2004-12-07 Odyssey Thera Inc. Protein fragment complementation assay (PCA) for the detection of protein-protein, protein-small molecule and protein nucleic acid interactions based on the E. coli TEM-1 β-Lactamase
US7855167B2 (en) * 1998-02-02 2010-12-21 Odyssey Thera, Inc. In vivo screening of protein-protein interactions with protein-fragment complementation assays
WO2000018885A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
WO2000007014A2 (en) 1998-07-28 2000-02-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
EP1027608B1 (de) * 1998-07-30 2010-01-20 Odyssey Thera, Inc. Eiweisbruchstückergänzungstests
CA2345392A1 (en) * 1998-09-24 2000-03-30 Duke University Method of measuring protein-protein interactions in living cells
US20040038317A1 (en) * 1999-03-15 2004-02-26 Kalobios, Inc. Breakpoint fusion fragment complementation system
US8148110B2 (en) 1999-03-15 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by β-lactamase reporter fragment complementation
AU780002B2 (en) * 1999-05-24 2005-02-24 Boston Biomedical Research Institute Incorporated Method for generating split, non-transferable genes that are able to express an active protein product
US20040096938A1 (en) * 1999-05-24 2004-05-20 Ming-Qun Xu Method for generating split, non-transferable genes that are able to express an active protein product
EP1183347A1 (de) * 1999-05-25 2002-03-06 Panorama Research, Inc. Durch wechselwirkung aktivierte proteine
US6673554B1 (en) * 1999-06-14 2004-01-06 Trellie Bioinformatics, Inc. Protein localization assays for toxicity and antidotes thereto
CA2377513A1 (en) * 1999-06-25 2001-01-04 Universitat Zurich Hetero-associating coiled-coil peptides
AU6054900A (en) * 1999-06-26 2001-01-31 Odyssey Pharmaceuticals, Inc. An in vivo library-versus-library selection of optimized protein-protein interactions
WO2001001137A1 (en) * 1999-06-30 2001-01-04 Children's Medical Center Corporation Fusion protein and uses thereof
WO2001007598A1 (en) * 1999-07-22 2001-02-01 Children's Medical Center Corporation EXPRESSION CLONING USING A TAGGED cDNA LIBRARY
EP1248840A2 (de) * 2000-01-13 2002-10-16 Panorama Research, Inc. Zirkulärpermutierte, wechselwirkungsaktive proteine
WO2001053479A2 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Molecular switches ii
WO2001060840A2 (en) * 2000-02-14 2001-08-23 Board Of Regents, The University Of Texas System Complementation assay assessing protein solubility and folding
US6727070B2 (en) 2000-02-14 2004-04-27 The Board Of Regents, The University Of Texas System Protein/solubility folding assessed by structural complementation
CA2384561A1 (en) 2000-05-12 2001-11-22 Yale University Methods of detecting interactions between proteins, peptides or libraries thereof using fusion proteins
WO2001088168A2 (en) * 2000-05-12 2001-11-22 Odyssey Pharmaceuticals, Inc. Mapping molecular interactions in plants with protein fragments complementation assays
EP1283878B1 (de) * 2000-05-22 2005-07-27 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Auf rezeptorgrundlage arbeitende screening-verfahren für protein wechselwirkungen
EP2149604A1 (de) 2000-09-08 2010-02-03 Universität Zürich Entnahme von Repeat-Proteinen mit Repeat-Modulen
GB0022458D0 (en) * 2000-09-13 2000-11-01 Medical Res Council Directed evolution method
US20030165873A1 (en) * 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
DE10110449A1 (de) * 2001-03-05 2002-09-19 Lisa Wiesmueller Testsystem zur Bestimmung von Genotoxizitäten
US20020177217A1 (en) * 2001-03-26 2002-11-28 Massachusetts Institute Of Technology Method for studying protein-protein interactions
WO2002090593A1 (en) * 2001-05-09 2002-11-14 Discoverx, Inc. Screening for enzyme inhibitors
EP1499885B1 (de) * 2001-08-01 2009-10-21 Cellomics, Inc. Neue fusionsproteine und molekulare bindungsassays
GB0118995D0 (en) * 2001-08-03 2001-09-26 Univ Wales Medicine Detection of mutations in nucleic acids
PT1434871T (pt) 2001-09-20 2017-04-05 Immunex Corp Seleção de células que expressam polipéptidos heteroméricos
AU2007200686B2 (en) * 2001-09-20 2011-07-14 Immunex Corporation Selection of cells expressing heteromeric polypeptides
GB0127564D0 (en) 2001-11-16 2002-01-09 Medical Res Council Emulsion compositions
EP1451214A2 (de) 2001-11-26 2004-09-01 Hybrigenics Protein-protein-wechselwirkungen beim human immunodeficiency virus
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US6936427B2 (en) * 2002-02-08 2005-08-30 Trellis Bioscience, Inc. Real time detection of intermolecular interaction
US7432063B2 (en) * 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7335478B2 (en) * 2002-04-18 2008-02-26 Kalobios Pharmaceuticals, Inc. Reactivation-based molecular interaction sensors
SE0200531D0 (sv) * 2002-02-22 2002-02-22 Avaris Ab Novel biomolecular complexes, method for their production and use
DE60317330T2 (de) * 2002-03-25 2008-08-21 Applera Corp., Bedford Systeme und verfahren zum nachweis der funktion nukleärer rezeptoren unter verwendung von reporterenzymmutanten komplementierungen
AU2003234327B2 (en) * 2002-05-01 2008-05-29 Trellis Bioscience, Inc. Binary or polynary targeting and uses thereof
GB0214553D0 (en) * 2002-06-25 2002-08-07 Univ Leeds Reporter module molecules having active ion channel activity
WO2004033485A2 (en) * 2002-10-09 2004-04-22 The Trustees Of Boston University Nucleic acid supported protein complementation
US9740817B1 (en) 2002-10-18 2017-08-22 Dennis Sunga Fernandez Apparatus for biological sensing and alerting of pharmaco-genomic mutation
WO2005003375A2 (en) 2003-01-29 2005-01-13 454 Corporation Methods of amplifying and sequencing nucleic acids
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
WO2005001115A2 (en) * 2003-05-30 2005-01-06 Odyssey Thera, Inc. Monitoring gene silencing and annotating gene function in living cells
EP1641809B2 (de) 2003-07-05 2018-10-03 The Johns Hopkins University Verfahren und zusammensetzungen zum nachweis und zur auflistung genetischer variationen
US8346482B2 (en) 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
WO2005038029A2 (en) 2003-10-10 2005-04-28 Promega Corporation Luciferase biosensor
GB0329353D0 (en) * 2003-12-19 2004-01-21 Amersham Biosciences Uk Ltd Cytochrome C protein and assay
US20050186606A1 (en) * 2004-02-11 2005-08-25 Schroeder Benjamin G. Methods and compositions for detecting nucleic acids
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
AU2005250333A1 (en) * 2004-04-16 2005-12-15 Genentech, Inc. Omi PDZ modulators
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
EP2400030B1 (de) 2004-05-18 2016-01-20 The Board of Trustees of the Leland Stanford Junior University Detektion von Proteintranslokation durch Beta-Galactosidase-Reporter-Fragmentkomplementierung
US20090221440A1 (en) * 2004-07-12 2009-09-03 Board Of Regents, The University Of Texas System Methods and compositions related to identifying protein-protein interactions
CA2574881C (en) 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
US20060040338A1 (en) 2004-08-18 2006-02-23 Odyssey Thera, Inc. Pharmacological profiling of drugs with cell-based assays
EP1799812A4 (de) 2004-09-16 2009-09-09 Gamida Cell Ltd Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
US20060094059A1 (en) * 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
EP1797427A4 (de) * 2004-09-22 2009-04-08 Odyssey Thera Inc Verfahren zur identifizierung neuer arzneimittel-leads und neuer therapeutischer verwendungen für bekannte arzneimittel
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US20060094682A1 (en) 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
EP1812038A1 (de) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domäne als leptin-rezeptor-antagonisten
US20060160109A1 (en) * 2004-11-22 2006-07-20 Odyssey Thera, Inc. Harnessing network biology to improve drug discovery
US20070212677A1 (en) * 2004-11-22 2007-09-13 Odyssey Thera, Inc. Identifying off-target effects and hidden phenotypes of drugs in human cells
AU2005314236A1 (en) * 2004-12-04 2006-06-15 The Regents Of The University Of California Los Alamos National Laboratory Protein-protein interaction detection system using fluorescent protein microdomains
US20060204999A1 (en) * 2005-03-14 2006-09-14 Stephen Macevicz Detecting molecular complexes
NZ565938A (en) * 2005-08-19 2011-10-28 Commw Scient Ind Res Org Arachnocampa (Diptera) ATP-dependent luciferases
EP1948825A2 (de) * 2005-10-27 2008-07-30 The Trustees Of Boston University Aktivierte spaltpolypeptide und verfahren zu deren herstellung und verwendung
CN101365805A (zh) * 2005-10-27 2009-02-11 波士顿大学董事会 使用蛋白质互补在体内实时检测核酸
GB0523954D0 (en) * 2005-11-24 2006-01-04 Ucb Celltech Bioassays
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US7601517B2 (en) 2006-01-10 2009-10-13 Stanford University Split protein self complementing fragments, systems, and methods of use thereof
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
JP2009526519A (ja) * 2006-01-17 2009-07-23 セルーメン、インコーポレイテッド 生物学的システム応答の予測方法
WO2007120522A2 (en) 2006-04-03 2007-10-25 Promega Corporation Permuted and nonpermuted luciferase biosensors
JP5290148B2 (ja) 2006-04-10 2013-09-18 ジェネンテック， インコーポレイテッド Ｄｉｓｈｅｖｅｌｅｄ（Ｄｖｌ）ＰＤＺ修飾因子
US20070254338A1 (en) * 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2481815B1 (de) 2006-05-11 2016-01-27 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen
US9074242B2 (en) 2010-02-12 2015-07-07 Raindance Technologies, Inc. Digital analyte analysis
CN101484806A (zh) 2006-05-17 2009-07-15 协乐民公司 一种对组织进行自动分析的方法
US8178654B2 (en) 2006-05-23 2012-05-15 Stanford University Estrogen receptor intramolecular folding systems, estrogen receptor intramolecular folding sensors, methods of use thereof, methods of detecting ER ligands, and methods of detecting ER agonists and antagonists
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008133709A2 (en) * 2006-10-27 2008-11-06 Trustees Of Boston University Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production
EP2095119A2 (de) * 2006-11-10 2009-09-02 Cellumen, Inc. Biosensoren für protein-protein-interaktion und verfahren zu ihrer verwendung
JP2010517945A (ja) * 2007-02-05 2010-05-27 パンバイオ・リミテツド 均一インビトロｆｅｃアッセイ及び成分
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US20090075313A1 (en) * 2007-05-04 2009-03-19 Stanford University Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems
JP5137266B2 (ja) 2007-08-01 2013-02-06 独立行政法人科学技術振興機構 抗原濃度測定法
SI2188313T1 (en) 2007-08-21 2018-04-30 Amgen, Inc. HUMAN C-FMS ANTIGEN TRANSFER PROTEIN
WO2009032664A2 (en) * 2007-08-31 2009-03-12 The Regents Of The University Of Michigan Methods and compositions for increasing biological molecule stability
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2210104A4 (de) * 2007-11-01 2011-02-23 Univ Arizona State Zellfreie verfahren zum nachweis von protein-ligand-wechselwirkungen
CA2705923A1 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
WO2009111073A2 (en) * 2008-03-06 2009-09-11 Odyssey Thera, Inc. High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
WO2009142735A2 (en) * 2008-05-19 2009-11-26 Promega Corporation LUCIFERASE BIOSENSORS FOR cAMP
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP2315629B1 (de) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Tröpfchenbibliotheken
CA2734895C (en) * 2008-08-18 2014-06-17 Discoverx Corporation Receptor tyrosine kinase assays
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
US9388406B2 (en) 2008-11-17 2016-07-12 Cornell University System useful for reporting protein-protein interactions in the bacterial periplasm
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP3415235A1 (de) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation von mikrofluidiktröpfchen
SG177395A1 (en) 2009-07-07 2012-02-28 Agency Science Tech & Res Methods of identifying a pair of binding partners
US8524457B2 (en) 2009-09-22 2013-09-03 William Patterson Method for the selection of specific affinity binders by homogeneous noncompetitive assay
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
WO2011143339A1 (en) 2010-05-11 2011-11-17 Promega Corporation Mutant protease biosensors with enhanced detection characteristics
US9290794B2 (en) 2010-05-11 2016-03-22 Promega Corporation Mutant protease biosensors with enhanced detection characteristics
EP3447155A1 (de) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwichassays in tröpfchen
MX354481B (es) 2010-10-27 2018-03-07 Amgen Inc Anticuerpos dkk1 y métodos de uso.
WO2012069655A2 (en) 2010-11-26 2012-05-31 Molecular Partners Ag Improved n-terminal capping modules for designed ankyrin repeat proteins
EP3412778A1 (de) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Verfahren zur bildung gemischter tröpfchen
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
CN103649118A (zh) 2011-03-01 2014-03-19 安进公司 双特异性结合剂
EP3553527A1 (de) 2011-03-17 2019-10-16 Cernostics, Inc. Systeme und zusammensetzungen zur diagnose von barrett-ösophagen und verfahren zur verwendung davon
KR20140039203A (ko) 2011-04-29 2014-04-01 얀센 바이오테크 인코포레이티드 Il4/il13 결합 반복 단백질 및 용도
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US9556470B2 (en) 2011-06-02 2017-01-31 Raindance Technologies, Inc. Enzyme quantification
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013033080A1 (en) * 2011-08-29 2013-03-07 Wayne State University Device and method for optimizing photobiological processes
RU2014118491A (ru) 2011-10-14 2015-11-20 Дженентек, Инк. Активаторы зимогенов
CN104220460A (zh) 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
BR112014020119A2 (pt) 2012-02-13 2020-10-27 Gamida-Cell Ltd cultura de células-tronco mesenquimais
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
WO2013137920A1 (en) 2012-03-16 2013-09-19 Genentech, Inc. Engineered conformationally-stabilized proteins
SI3431492T1 (sl) 2012-04-27 2021-07-30 Novo Nordisk A/S Antigen-vezavni proteini liganda človeškega CD30
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
EP2738180A1 (de) 2012-11-30 2014-06-04 Molecular Partners AG Bindeproteine mit mindestens zwei Bindedomänen gegen HER2
EP2970451A1 (de) 2013-03-14 2016-01-20 Amgen Inc. Chrdl-1-antigenbindende proteine und behandlungsmethoden damit
DK2970412T3 (da) 2013-03-15 2022-08-29 Promega Corp Aktivering af bioluminescens via strukturel komplementering
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
WO2014144632A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
SG11201705495XA (en) 2014-01-14 2017-08-30 Asedasciences Ag Identification of functional cell states
AU2015224552A1 (en) * 2014-03-03 2016-09-15 Novogy, Inc. Reducing horizontal gene transfer of functional proteins
JP6159486B2 (ja) 2014-06-12 2017-07-05 アクシオン バイオシステムズ， インコーポレイテッド 光学的刺激を有するマルチウェル微小電極アレイ
JP6438118B2 (ja) * 2014-08-27 2018-12-12 エルジー エレクトロニクス インコーポレイティド 無線通信システムにおけるデータ送信方法及びこのための装置
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
CN105406948B (zh) * 2014-09-12 2020-03-06 中兴通讯股份有限公司 一种实现并行多用户数据传输的方法及主节点
RU2680193C2 (ru) * 2014-10-01 2019-02-18 ЭлДжи ЭЛЕКТРОНИКС ИНК. Способ передачи данных в системе беспроводной связи и устройство для его осуществления
US9942055B2 (en) * 2015-02-12 2018-04-10 Intel IP Corporation Apparatus, system and method of multicast communication
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
WO2017112824A2 (en) 2015-12-23 2017-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
WO2017182437A1 (en) 2016-04-18 2017-10-26 Universität Innsbruck Quantification of an interaction between a ras protein and a raf protein
EP3493855A4 (de) 2016-08-02 2020-04-01 ISI Life Sciences, Inc. Zusammensetzungen und verfahren zur detektion von krebszellen in einer gewebeprobe
US10239891B2 (en) * 2017-05-15 2019-03-26 Indicator Systems International, Inc. Compositions to detect remnant cancer cells
US10982252B2 (en) 2016-08-08 2021-04-20 Technology Innovation Momentum Fund (Israel) Limited Partnership Bacterial systems for analyzing ubiquitylated polypeptides
EP3519830B1 (de) 2016-09-29 2023-07-19 KinCon biolabs GmbH Aktivitäts-anpassender reportervektor enthaltend eine kinase mit voller länge
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
WO2018128454A1 (ko) 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
CN110831969B (zh) 2017-06-20 2024-06-21 安进公司 使用抑胃肽受体（gipr）结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法
JP7504025B2 (ja) 2017-08-04 2024-06-21 アムジエン・インコーポレーテツド Ｃｙｓ－ｍａｂのコンジュゲーション方法
WO2019030759A1 (en) 2017-08-08 2019-02-14 Technology Innovation Momentum Fund (Israel) Limited Partnership CHLORAMPHENICOL-RESISTANT TRUNCATED PROTEIN AND USES THEREOF
WO2019117684A1 (ko) 2017-12-14 2019-06-20 에이비엘바이오 주식회사 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
GB2590302B (en) 2018-07-06 2023-03-22 The Regents Of The Univ Of Colorado A Body Corporate Existing Under The Laws Of The State Of Colorad Genetically encoded system for constructing and detecting biologically active agents
CN111198272B (zh) * 2018-11-20 2023-09-08 香港理工大学深圳研究院 体外检测蛋白间相互作用的方法和检测试剂盒及其应用
EP3894549B1 (de) 2018-12-10 2024-07-31 Amgen Inc. Mutierte piggybac-transposase
CA3153963A1 (en) * 2019-09-09 2021-03-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb
US20220389099A1 (en) 2019-11-04 2022-12-08 Amgen Inc. Methods for treating leukemia
CA3165802A1 (en) * 2020-01-25 2021-07-29 The Trustees Of The University Of Pennsylvania Compositions for small molecule control of precise base editing of target nucleic acids and methods of use thereof
IL297237A (en) 2020-04-17 2022-12-01 Regeneron Pharma Detection tests for antibodies that neutralize the corona virus
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
TW202233660A (zh) 2020-10-30 2022-09-01 美商安進公司 過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
CN112375775A (zh) * 2020-11-16 2021-02-19 中南民族大学 一种基于片段化萤光素酶-dna嵌合体互补的发光体系、构建方法及其应用
KR20230110298A (ko) * 2020-11-17 2023-07-21 너드 바이오 엘엘씨 고처리량 약물 스크리닝 방법
WO2022232376A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
UY39807A (es) 2021-06-10 2022-12-30 Amgen Inc VARIANTES GENOMODIFICADAS DE LA NRG-1 CON UNA SELECTIVIDAD MEJORADA FRENTE AL ErbB4 PERO NO FRENTE A
TW202328442A (zh) 2021-09-10 2023-07-16 美商安進公司 平臺宿主對ｉｇｆ—培養基之適應
WO2023183231A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
WO2024064744A2 (en) * 2022-09-20 2024-03-28 Dna Twopointo, Inc. Engineered split dhfr-based methods and systems for selecting cells that have stably acquired a heterologous polynucleotide
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024089297A1 (en) 2022-10-28 2024-05-02 Urban Joerg Novel fluorescent and bioluminescent proteins and reporter systems for ratiometric measurement of luminescence
WO2024163713A1 (en) 2023-02-02 2024-08-08 Amgen Inc. Mitigation of therapeutic protein fragmentation during cell culture harvest processes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2068190C (en) * 1991-05-15 1996-12-17 Microgenics Corporation Methods and compositions for enzyme complementation assays using the omega region of beta-galactosidase
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
US5585245A (en) * 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
US5610015A (en) * 1995-03-23 1997-03-11 Wisconsin Alumni Research Foundation System to detect protein-RNA interactions
US6872871B2 (en) * 1998-02-02 2005-03-29 Odyssey Thera Inc. Mapping molecular interactions in plants with protein fragments complementation assays
CA2196496A1 (en) * 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US6897017B1 (en) * 1997-01-31 2005-05-24 Odyssey Thera Inc. Vivo library-versus-library selection of optimized protein-protein interactions
US6828099B2 (en) * 1998-02-02 2004-12-07 Odyssey Thera Inc. Protein fragment complementation assay (PCA) for the detection of protein-protein, protein-small molecule and protein nucleic acid interactions based on the E. coli TEM-1 β-Lactamase

Also Published As

Publication number Publication date
US20030049688A1 (en) 2003-03-13
US7160691B2 (en) 2007-01-09
US7989218B2 (en) 2011-08-02
ATE301835T1 (de) 2005-08-15
US6270964B1 (en) 2001-08-07
JP2002508832A (ja) 2002-03-19
CA2196496A1 (en) 1998-07-31
EP0966685B1 (de) 2005-08-10
US6929916B2 (en) 2005-08-16
DE69831136T2 (de) 2006-06-08
EP0966685A1 (de) 1999-12-29
US20130022999A1 (en) 2013-01-24
EP1605042A3 (de) 2011-01-12
ES2247673T3 (es) 2006-03-01
EP1605042A2 (de) 2005-12-14
EP0966685B9 (de) 2006-03-15
WO1998034120A1 (en) 1998-08-06
AU5850598A (en) 1998-08-25
US20040038298A1 (en) 2004-02-26
US8192944B2 (en) 2012-06-05
US20110287950A1 (en) 2011-11-24
US20070148682A1 (en) 2007-06-28
DE69831136D1 (de) 2005-09-15
US6428951B1 (en) 2002-08-06
JP4262778B2 (ja) 2009-05-13

Similar Documents

Publication Publication Date Title
DK0966685T3 (da) Protein-fragment-komplementationsassays til påvisning af biomolekylære interaktioner
Young et al. Recombinant protein expression and purification: a comprehensive review of affinity tags and microbial applications
Sieber et al. Selecting proteins with improved stability by a phage-based method
US5843746A (en) Biotinated firefly luciferase, a gene for biotinated firefly luciferase, a recombinant DNA, a process for producing biotinated luciferase and a bioluminescent analysis method
Sidhu Phage display in pharmaceutical biotechnology
Arndt et al. Comparison of in vivo selection and rational design of heterodimeric coiled coils
Ito et al. Cellular functions, mechanism of action, and regulation of FtsH protease
Khmelinskii et al. Incomplete proteasomal degradation of green fluorescent proteins in the context of tandem fluorescent protein timers
Murtaugh et al. A combinatorial histidine scanning library approach to engineer highly pH‐dependent protein switches
Randles et al. Ubiquitin and its binding domains
US10202466B2 (en) Linked peptide fluorogenic biosensors
WO2002092771A3 (en) Specific binding proteins and uses thereof
EP2172486A3 (de) Monoklonaler Antikörper gegen ein Prion und dessen Verwendung zum Nachweis von Prionen
WO2000007038A3 (en) Protein fragment complementation assays
US20060068421A1 (en) Compositions and methods for phage display of polypeptides
Rowley et al. Prediction of the immunodominant epitope of the pyruvate dehydrogenase complex E2 in primary biliary cirrhosis using phage display
Weaver-Feldhaus et al. Directed evolution for the development of conformation-specific affinity reagents using yeast display
Zhang et al. Sortase A‐mediated synthesis of ligand‐grafted cyclized peptides for modulating a model protein‐protein interaction
US20020155502A1 (en) Affinity maturation by competitive selection
CA2490538A1 (en) New assays for preimplantation factor and preimplantation factor peptides
WO2003053921A3 (en) Mutant proteinase inhibitors and uses thereof
CA2597545A1 (en) Antibody for assay of adamts13 activity and method for assaying the activity
US20050130262A1 (en) Mutated photoproteins and their uses
Ha et al. Construction of allosteric protein switches by alternate frame folding and intermolecular fragment exchange
WO2019072977A1 (en) NANOCORPS ANTI-IGG